VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer
10.1158/1535-7163.MCT-12-0466
Saved in:
Main Authors: | Hart, S., Novotny-Diermayr, V., Goh, K.C., Williams, M., Tan, Y.C., Ong, L.C., Cheong, A., Ng, B.K., Amalini, C., Madan, B., Nagaraj, H., Jayaraman, R., Pasha, K.M., Ethirajulu, K., Chng, W.J., Mustafa, N., Goh, B.C., Benes, C., McDermott, U., Garnett, M., Dymock, B., Wood, J.M. |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
2016
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/125481 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
mTOR, autophagy, and reprogramming
by: Tang, B.L
Published: (2020) -
Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression
by: Wu, M, et al.
Published: (2020) -
Role of mTOR inhibitor in cholangiocarcinoma cell progression
by: Penpak Moolthiya, et al.
Published: (2018) -
28S rRNA is inducibly pseudouridylated by the mTOR pathway translational control in CHO cell cultures
by: Courtes, F.C., et al.
Published: (2014) -
Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis
by: Koh K.X., et al.
Published: (2020)